Fig. 3 | Scientific Reports

Fig. 3

From: Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy

Fig. 3

Tumor response. (A) Waterfall plot of optimal changes from baseline in intracranial and extracranial target lesions in 15 patients. *, 6 patients had no intracranial target lesions; #, 1 patient had no extracranial target lesion. (B) Swimmer plot of PFS for 15 patients. SD, stable disease; PR, partial response; PD, progressive disease; CNS-PFS, central nervous system progression-free survival.

Back to article page